BioSpace News Archive

Healthtech Solutions, Inc. (OTC: HLTT) (“Healthtech” or the “Company”), announced today that Edward (Ned) Swanson, M.D., was named Chief Executive Officer.

Researchers have discovered new ways in which the COVID-19 virus causes human immune cells to overreact, a deadly part of the disease

Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, President and CEO, will participate virtually in a fireside chat during the 2021 RBC Capital Markets Global Healthcare Conference

Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported the grant of inducement awards to Cokey Nguyen, its Senior Vice President, Chief Scientific Officer.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (“Regulus”), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 11:35 A.M. ET.

Axonics, Inc. (Nasdaq: AXNX), (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4,025,000 shares of common stock at the public offering price of $50.00 per share,

Quidel Corporation, a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that its non-prescription QuickVue® At-Home OTC COVID-19 Test is now available in the United States to consumers for online order through e-commerce retailer Amazon.

Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2021 corporate update call on Thursday, May 20th at 5:00 PM ET.

BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on May 4, 2021, the compensation committee of BridgeBio’s board of directors granted 27 new employees restricted stock units for an aggregate of 70,949 shares of the Company’s common stock.